Literature DB >> 14981546

FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.

Blanca Scheijen1, Hai T Ngo, Hyun Kang, James D Griffin.   

Abstract

In about 30% of the patients with acute myeloid leukemia, activating FLT3 receptor mutations have been identified, often as in-frame internal tandem duplications (ITD) at the juxtamembrane domain of the receptor. FLT3-ITD receptors exhibit constitutive tyrosine kinase activity in the absence of FLT3 ligand (FL) binding, and when expressed in cytokine-dependent cell lines and primary hematopoietic cells suppress programmed cell death and increase cell division. However, the signaling pathways important for transformation, in particular the nuclear targets, are unknown. Here we demonstrate that FLT3-ITD expression in Ba/F3 cells results in activation of Akt and concomitant phosphorylation of the Forkhead family member Foxo3a. Phosphorylation of Foxo proteins through FLT3-ITD signaling promotes their translocation from the nucleus into the cytoplasm, which requires the presence of conserved Akt phosphorylation sites in Forkhead transcription factors and PI3K activity. Induction of Foxo3a phosphorylation by FLT3-ITD receptors in Ba/F3 cells correlates with the suppression of Foxo-target genes p27Kip1 and the proapoptotic Bcl-2 family member Bim. Specifically, FLT3-ITD expression prevents Foxo3a-mediated apoptosis and upregulation of p27Kip1 and Bim gene expression. These data indicate that the oncogenic tyrosine kinase FLT3 can negatively regulate Foxo transcription factors, thereby promoting cell survival and proliferation. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981546     DOI: 10.1038/sj.onc.1207456

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.

Authors:  Shan Lin; Anetta Ptasinska; Xiaoting Chen; Mahesh Shrestha; Salam A Assi; Paulynn S Chin; Maria R Imperato; B J Aronow; Jingsong Zhang; Matthew T Weirauch; Constanze Bonifer; James C Mulloy
Journal:  Blood       Date:  2017-07-14       Impact factor: 22.113

Review 2.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

Authors:  Sophie Park; Nicolas Chapuis; Jérôme Tamburini; Valérie Bardet; Pascale Cornillet-Lefebvre; Lise Willems; Alexa Green; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

3.  Evidence for AKT-independent regulation of FOXO1 and FOXO3 in haematopoietic stem and progenitor cells.

Authors:  Raymond Liang; Pauline Rimmelé; Carolina L Bigarella; Safak Yalcin; Saghi Ghaffari
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

4.  Treatment of FLT3-ITD acute myeloid leukemia.

Authors:  Amir T Fathi; Yi-Bin Chen
Journal:  Am J Blood Res       Date:  2011-09-09

5.  Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia.

Authors:  Steven M Kornblau; Neera Singh; YiHua Qiu; Wenjing Chen; Nianxiang Zhang; Kevin R Coombes
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

Review 6.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

Review 7.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

8.  Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.

Authors:  S Chu; T McDonald; R Bhatia
Journal:  Leukemia       Date:  2010-03-04       Impact factor: 11.528

9.  Remarkably reduced expression of FoxO3a in metaplastic colorectum, primary colorectal cancer and liver metastasis.

Authors:  Le-Ya He; Xin Wei; Lei Du; Lu Liu; Feng Xu; Jiang Min; Chuan Li; De-Ding Tao; Quan Chen; Jun-Bo Hu; Jian-Ping Gong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17

Review 10.  ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.

Authors:  Jianbiao Zhou; Boon-Cher Goh; Daniel H Albert; Chien-Shing Chen
Journal:  J Hematol Oncol       Date:  2009-07-30       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.